Lupus Forum

JAKi in the treatment of SLE

Join Professors Ed Vital, Cynthia Aranow, Richard Furie, and Chris Edwards as they discuss the role of the JAK-STAT pathway, the emerging evidence of using JAK Inhibitors in clinical trials (SLEek trial), and the need for long-term data and the challenges faced.

Discussing Lupus: Insights into belimumab and anifrolumab in SLE

Our Steering Committee Member Professor Maria Dall’Era is joined by Professor Vibeke Strand in the latest Lupus Forum podcast. Together they discuss the efficacy of belimumab treatment in patients with SLE. They will also discuss the impact of long-term anifrolumab treatment on patients’ perceived health status and health-related quality of life.

Advances in Lupus Nephritis Podcast

Join Professors Liz Lightstone and Maria Dall’Era for an expert-led discussion focused on lupus nephritis, exploring its current standard of care, practical implementation in clinical settings, and evolving treatment landscape. This podcast will delve into the latest advances in the management of lupus nephritis, including emerging therapies such as obinutuzumab, and examine the future treatment pipeline.

Discussing Lupus: Insights into belimumab and telitacicept in SLE

Our Steering Committee Member Professor Chi-Chiu Mok is joined by Professor Chiu Wai Shirley Chan in the latest Lupus Forum podcast. Together they discuss the use of machine learning to identify clusters of SLE patients based on peripheral B cell and plasma cell subsets. They will also discuss the potential predictors of efficacy and safety of belimumab and telitacicept in SLE, and the altering effect of belimumab on autoimmunity in SLE.

Advances in the treatment of SLE: Highlights Podcast

Join Professors Ed Vital, Cynthia Aranow, and Richard Furie as they discuss the key takeaways from their recent webinar focusing on the following topics: new and emerging pathways in the treatment of SLE, advances in treatment of SLE, and The challenges confronting SLE clinical trials.

Discussing Lupus: Belimumab in mucocutaneous lupus erythematosus and anifrolumab in SLE

Our Steering Committee experts Professor Victoria Werth and Chris Edwards join the latest Lupus Forum podcast to discuss the effect of belimumab vs placebo on mucocutaneous manifestations of SLE, and the long-term impact of anifrolumab vs placebo on LLDAS and DORIS attainment in patients with SLE.